Table 2. Correlation between miR-4270 expression and the clinicopathological features of LAD patients with and without BM.
| Characteristics | miR-4270 expression levels of discovery group |
miR-4270 expression levels of validation group |
miR-4270 expression levels of full group |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Low (n = 44) | High (n = 43) | P | Low (n = 34) | High (n = 34) | P | Low (n = 78) | High (n = 77) | P | |
| Gender | |||||||||
| Male | 26 (59.1%) | 24 (60.5%) | 0.757 | 21(50.0%) | 21 (50.0%) | 1.000 | 47 (60.3%) | 45 (58.4%) | 0.818 |
| Female | 18 (40.9%) | 19 (39.5%) | 13 (50.0%) | 13 (50.0%) | 31 (39.7%) | 32 (41.6%) | |||
| Age | |||||||||
| ≤ 60 | 25 (56.8%) | 22 (51.2%) | 0.597 | 15 (44.1%) | 14 (41.2%) | 0.806 | 40 (51.3%) | 36 (46.8%) | 0.573 |
| > 60 | 19 (43.2%) | 21 (48.8%) | 19 (55.9%) | 20 (58.8%) | 38 (48.7%) | 41 (53.2%) | |||
| Tumor stage | |||||||||
| T1+ T2 | 36 (81.8%) | 38 (88.4%) | 0.391 | 32 (94.1%) | 30 (88.2%) | 0.388 | 68 (87.2%) | 68 (88.2%) | 0.830 |
| T3 | 8 (18.2%) | 5 (11.6%) | 2 (5.9%) | 4 (11.8%) | 10 (12.8%) | 9 (11.7%) | |||
| Histologic grade | |||||||||
| Well/moderate | 29 (65.9%) | 27 (62.8%) | 0.761 | 21 (61.8%) | 25 (73.5%) | 0.300 | 34 (43.6%) | 43 (55.8%) | 0.127 |
| Poor/NS | 15 (34.1%) | 16 (37.2%) | 13 (38.2%) | 9 (26.5%) | 44 (56.4%) | 34 (44.2%) | |||
| Lymph node ratio | |||||||||
| ≤1/3 | 20 (45.5%) | 16 (37.2%) | 0.067 | 21 (61.8%) | 22 (64.7%) | 0.801 | 35 (44.9%) | 44 (57.1%) | 0.127 |
| >1/3 | 24 (54.5%) | 27 (62.8%) | 13 (39.2%) | 12 (35.3%) | 43 (55.1%) | 33 (42.9%) | |||
| Brain metastasis | |||||||||
| BM | 26 (59.1%) | 6 (14.0%) | 0.000 | 21 (61.8%) | 9 (26.5%) | 0.003 | 47 (60.3%) | 15 (19.5%) | 0.000 |
| NBM | 18 (40.9%) | 37 (86.0%) | 13 (38.2%) | 25 (73.5%) | 31 (39.7%) | 62 (80.5%) | |||
BM, brain metastasis; NBM, no brain metastasis; NS, not stated.